Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Rating) CFO Kamran Alam sold 7,476 shares of the stock in a transaction dated Thursday, August 18th. The stock was sold at an average price of $3.87, for a total value of $28,932.12. Following the transaction, the chief financial officer now owns 290,645 shares of the company's stock, valued at approximately $1,124,796.15. The transaction was disclosed in a filing with the SEC, which is available at this link.

Kamran Alam also recently made the following trade(s):

• On Monday, August 22nd, Kamran Alam sold 9,717 shares of Taysha Gene Therapies stock. The stock was sold at an average price of $3.50, for a total value of $34,009.50.

Taysha Gene Therapies Trading Down 8.3 %

Shares of NASDAQ:TSHA opened at $3.43 on Tuesday. Taysha Gene Therapies, Inc. has a 52-week low of $2.33 and a 52-week high of $21.90. The company has a market capitalization of $140.95 million, a P/E ratio of -0.71 and a beta of 0.99. The company has a 50-day simple moving average of $4.01 and a 200 day simple moving average of $4.73. The company has a debt-to-equity ratio of 1.15, a quick ratio of 1.79 and a current ratio of 1.79.

Analysts Set New Price Targets

Institutional Investors Weigh In On Taysha Gene Therapies

Several hedge funds have recently bought and sold shares of TSHA. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. acquired a new stake in Taysha Gene Therapies in the 4th quarter valued at about $259,000. Northern Trust Corp lifted its position in Taysha Gene Therapies by 1.4% during the fourth quarter. Northern Trust Corp now owns 214,970 shares of the company's stock worth $2,504,000 after acquiring an additional 3,042 shares during the last quarter. ProShare Advisors LLC acquired a new stake in Taysha Gene Therapies during the fourth quarter worth approximately $121,000. GSA Capital Partners LLP acquired a new stake in Taysha Gene Therapies during the fourth quarter worth approximately $476,000. Finally, Virtus ETF Advisers LLC lifted its position in Taysha Gene Therapies by 39.3% during the fourth quarter. Virtus ETF Advisers LLC now owns 11,519 shares of the company's stock worth $134,000 after acquiring an additional 3,251 shares during the last quarter. 46.05% of the stock is currently owned by institutional investors and hedge funds.

Taysha Gene Therapies Company Profile

(Get Rating)

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.

Further Reading

• Get a free copy of the StockNews.com research report on Taysha Gene Therapies (TSHA)
• MarketBeat Podcast: Fantasy Football Strategy With Your Stock Portfolio
• Should You Buy These Copper Stocks Ahead Of Monster Demand?
• Three Industrial Stocks That Can Weather a Stormy Recession
• Bed Bath & Beyond Meat: Is BYND the Next Big Short Squeeze?
• Denbury Rises On Rumor Of A Sale, But Lags Other Energy Names

Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.